Operaciones Concert Pharm - CNCE CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.09 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.024068% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.001846% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | N/A |
| Abrir* | N/A |
| Cambio de 1 año* | N/A |
| Rango del día* | N/A |
| Rango de 52 semanas | 2.66-8.55 |
| Volumen medio (10 días) | 2.59M |
| Volumen medio (3 meses) | 43.80M |
| Capitalización de mercado | 401.24M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 47.94M |
| Ingresos | 42.00K |
| EPS | -2.93 |
| Dividendo (Rendimiento %) | N/A |
| Beta | 0.53 |
| Próxima fecha de resultados | May 3, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Mar 27, 2023 | 8.34 | 0.00 | 0.00% | 8.34 | 8.34 | 8.34 |
| Mar 14, 2023 | 8.34 | 0.00 | 0.00% | 8.34 | 8.34 | 8.34 |
| Mar 3, 2023 | 8.34 | 0.01 | 0.12% | 8.33 | 8.50 | 8.31 |
| Mar 2, 2023 | 8.33 | -0.01 | -0.12% | 8.34 | 8.34 | 8.30 |
| Mar 1, 2023 | 8.34 | 0.01 | 0.12% | 8.33 | 8.34 | 8.33 |
| Feb 28, 2023 | 8.34 | -0.01 | -0.12% | 8.35 | 8.35 | 8.34 |
| Feb 27, 2023 | 8.34 | 0.00 | 0.00% | 8.34 | 8.36 | 8.34 |
| Feb 24, 2023 | 8.34 | -0.01 | -0.12% | 8.35 | 8.35 | 8.33 |
| Feb 23, 2023 | 8.35 | 0.00 | 0.00% | 8.35 | 8.36 | 8.35 |
| Feb 22, 2023 | 8.34 | 0.02 | 0.24% | 8.32 | 8.36 | 8.32 |
| Feb 21, 2023 | 8.31 | -0.03 | -0.36% | 8.34 | 8.36 | 8.30 |
| Feb 17, 2023 | 8.34 | 0.00 | 0.00% | 8.34 | 8.37 | 8.33 |
| Feb 16, 2023 | 8.34 | 0.03 | 0.36% | 8.31 | 8.36 | 8.30 |
| Feb 15, 2023 | 8.31 | -0.01 | -0.12% | 8.32 | 8.33 | 8.29 |
| Feb 14, 2023 | 8.29 | 0.00 | 0.00% | 8.29 | 8.31 | 8.28 |
| Feb 13, 2023 | 8.28 | -0.02 | -0.24% | 8.30 | 8.31 | 8.28 |
| Feb 10, 2023 | 8.29 | 0.00 | 0.00% | 8.29 | 8.30 | 8.28 |
| Feb 9, 2023 | 8.28 | -0.06 | -0.72% | 8.34 | 8.35 | 8.27 |
| Feb 8, 2023 | 8.31 | -0.02 | -0.24% | 8.33 | 8.33 | 8.30 |
| Feb 7, 2023 | 8.31 | -0.03 | -0.36% | 8.34 | 8.36 | 8.31 |
Concert Pharm Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| No events scheduled | ||
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos totales | 32.578 | 7.902 | 1.077 | 10.505 | 143.891 |
| Ingresos | 32.578 | 7.902 | 1.077 | 10.505 | 143.891 |
| Gastos totales de explotación | 110.086 | 80.549 | 80.092 | 66.089 | 52.674 |
| Gastos de venta/general/administración Gastos, total | 22.248 | 18.624 | 19.97 | 22.94 | 21.019 |
| Investigación y desarrollo | 87.555 | 61.624 | 59.816 | 43.149 | 30.223 |
| Ingresos de explotación | -77.508 | -72.647 | -79.015 | -55.584 | 91.217 |
| Ingresos por intereses (gastos), netos No operativos | -2.543 | -2.204 | 0.837 | -0.139 | 0.521 |
| Ingresos netos antes de impuestos | -80.051 | -74.851 | -78.166 | -55.711 | 95.339 |
| Ingresos netos después de impuestos | -80.051 | -74.766 | -78.166 | -56.024 | 95.639 |
| Beneficio neto antes de partidas extra. Elementos | -80.051 | -74.766 | -78.166 | -56.024 | 95.639 |
| Ingresos netos | -80.051 | -74.766 | -78.166 | -56.024 | 95.639 |
| Total Adjustments to Net Income | 0 | -0.444 | |||
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -80.051 | -74.766 | -78.166 | -56.024 | 95.195 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -80.051 | -74.766 | -78.166 | -56.024 | 95.195 |
| Beneficio neto diluido | -80.051 | -74.766 | -78.166 | -56.024 | 95.21 |
| Promedio ponderado de acciones diluidas | 34.405 | 31.2 | 23.74 | 23.37 | 23.442 |
| BPA diluido sin partidas extraordinarias | -2.32673 | -2.39635 | -3.29259 | -2.39726 | 4.06151 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA normalizado diluido | -2.32673 | -2.39635 | -3.29259 | -2.39726 | 4.10122 |
| Gastos (ingresos) extraordinarios | 0 | 1.432 | |||
| Otros, netos | 0 | 0 | 0.012 | 0.012 | 3.601 |
| Total de partidas extraordinarias | 0 | ||||
| Ajuste por dilución | 0.015 | ||||
| Depreciation / Amortization | 0.283 | 0.301 | 0.306 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0.013 | 0.543 | 32.017 | 0.005 |
| Ingresos | 0 | 0.013 | 0.543 | 32.017 | 0.005 |
| Gastos totales de explotación | 36.028 | 32.965 | 27.338 | 25.798 | 23.985 |
| Gastos de venta/general/administración Gastos, total | 5.467 | 5.909 | 5.393 | 5.537 | 5.409 |
| Investigación y desarrollo | 30.489 | 26.995 | 21.876 | 20.184 | 18.5 |
| Depreciation / Amortization | 0.072 | 0.061 | 0.069 | 0.077 | 0.076 |
| Ingresos de explotación | -36.028 | -32.952 | -26.795 | 6.219 | -23.98 |
| Ingresos por intereses (gastos), netos No operativos | -1.7 | -3.177 | 0.117 | -0.794 | 1.311 |
| Ingresos netos antes de impuestos | -37.728 | -36.129 | -26.678 | 5.425 | -22.669 |
| Ingresos netos después de impuestos | -37.728 | -36.129 | -26.678 | 5.425 | -22.669 |
| Beneficio neto antes de partidas extra. Elementos | -37.728 | -36.129 | -26.678 | 5.425 | -22.669 |
| Ingresos netos | -37.728 | -36.129 | -26.678 | 5.425 | -22.669 |
| Total Adjustments to Net Income | -0.01 | 0.01 | |||
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -37.728 | -36.129 | -26.678 | 5.415 | -22.659 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -37.728 | -36.129 | -26.678 | 5.415 | -22.659 |
| Beneficio neto diluido | -37.728 | -36.129 | -26.678 | 5.415 | -22.659 |
| Promedio ponderado de acciones diluidas | 36.687 | 35.659 | 34.09 | 34.083 | 33.954 |
| BPA diluido sin partidas extraordinarias | -1.02838 | -1.01318 | -0.78258 | 0.15888 | -0.66734 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -1.02838 | -1.01318 | -0.78258 | 0.15888 | -0.66734 |
| Otros, netos | 0 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 150.329 | 142.724 | 116.855 | 180.149 | 205.734 |
| Efectivo e inversiones a corto plazo | 143.099 | 131.937 | 111.813 | 160.839 | 203.165 |
| Cash | 8.786 | 7.274 | 10.261 | 8.379 | 19.557 |
| Efectivo y Equivalentes | 132.85 | 69.928 | 42.782 | 9.391 | 8.108 |
| Inversiones a corto plazo | 1.463 | 54.735 | 58.77 | 143.069 | 175.5 |
| Total deudores, neto | 0.218 | 3.177 | 0.332 | 16.571 | 0.783 |
| Accounts Receivable - Trade, Net | 0.218 | 0.686 | 0.072 | 16.015 | 0.155 |
| Prepaid Expenses | 6.997 | 7.61 | 4.567 | 2.739 | 1.786 |
| Total Assets | 165.316 | 159.263 | 137.471 | 192.547 | 211.736 |
| Property/Plant/Equipment, Total - Net | 13.827 | 15.331 | 17.005 | 8.919 | 2.165 |
| Property/Plant/Equipment, Total - Gross | 17.937 | 19.331 | 19.93 | 10.431 | 9.532 |
| Accumulated Depreciation, Total | -4.11 | -4 | -2.925 | -1.512 | -7.367 |
| Other Long Term Assets, Total | 1.16 | 1.208 | 1.253 | 1.157 | 1.591 |
| Total Current Liabilities | 16.12 | 10.178 | 17.268 | 8.749 | 6.445 |
| Accounts Payable | 2.606 | 0.23 | 0.881 | 1.277 | 0.658 |
| Accrued Expenses | 5.866 | 5.33 | 4.352 | 3.739 | 3.425 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 7.648 | 4.618 | 12.035 | 3.733 | 2.362 |
| Total Liabilities | 53.091 | 28.101 | 36.014 | 24.807 | 15.304 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 36.971 | 17.923 | 18.746 | 16.058 | 8.859 |
| Total Equity | 112.225 | 131.162 | 101.457 | 167.74 | 196.432 |
| Common Stock | 0.034 | 0.031 | 0.024 | 0.023 | 0.023 |
| Additional Paid-In Capital | 461.765 | 400.636 | 296.145 | 284.369 | 273.059 |
| Retained Earnings (Accumulated Deficit) | -349.498 | -269.447 | -194.681 | -116.515 | -76.243 |
| Other Equity, Total | -0.076 | -0.058 | -0.031 | ||
| Total Liabilities & Shareholders’ Equity | 165.316 | 159.263 | 137.471 | 192.547 | 211.736 |
| Total Common Shares Outstanding | 34.739 | 31.8622 | 23.8651 | 23.4376 | 23.1404 |
| Note Receivable - Long Term | 0 | 2.358 | 2.322 | 2.246 | |
| Unrealized Gain (Loss) | -0.137 | -0.407 | |||
| Redeemable Preferred Stock | 0 | 0 | |||
| Other Current Assets, Total | 0.015 | 0 | 0.143 | ||
| Preferred Stock - Non Redeemable, Net | 0 | ||||
| Total Preferred Shares Outstanding | 0.014 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 114.768 | 150.329 | 112.908 | 132.983 | 123.855 |
| Efectivo e inversiones a corto plazo | 109.905 | 143.099 | 106.223 | 124.845 | 115.036 |
| Cash | 14.423 | 8.786 | 7.817 | 3.554 | 7.964 |
| Efectivo y Equivalentes | 44.94 | 132.85 | 95.847 | 118.845 | 81.808 |
| Inversiones a corto plazo | 50.542 | 1.463 | 2.559 | 2.446 | 25.264 |
| Total deudores, neto | 0.995 | 0.218 | 0.476 | 0.241 | 2.452 |
| Accounts Receivable - Trade, Net | 0.744 | 0.218 | 0.476 | 0.24 | 0.079 |
| Prepaid Expenses | 3.868 | 6.997 | 6.167 | 7.882 | 6.367 |
| Total Assets | 129.411 | 165.316 | 128.208 | 148.705 | 139.991 |
| Property/Plant/Equipment, Total - Net | 13.484 | 13.827 | 14.133 | 14.544 | 14.947 |
| Other Long Term Assets, Total | 1.159 | 1.16 | 1.167 | 1.178 | 1.189 |
| Total Current Liabilities | 15.082 | 16.12 | 12.021 | 8.67 | 8.303 |
| Accounts Payable | 2.755 | 2.606 | 0.584 | 0 | 0.508 |
| Accrued Expenses | 2.707 | 5.866 | 4.101 | 3.435 | 2.528 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 9.62 | 7.648 | 7.336 | 5.235 | 5.267 |
| Total Liabilities | 52.845 | 53.091 | 29.046 | 25.989 | 25.952 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 37.763 | 36.971 | 17.025 | 17.319 | 17.649 |
| Total Equity | 76.566 | 112.225 | 99.162 | 122.716 | 114.039 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Common Stock | 0.034 | 0.034 | 0.031 | 0.031 | 0.031 |
| Additional Paid-In Capital | 463.876 | 461.765 | 412.576 | 409.452 | 406.198 |
| Retained Earnings (Accumulated Deficit) | -387.226 | -349.498 | -313.369 | -286.691 | -292.116 |
| Other Equity, Total | -0.118 | -0.076 | -0.076 | -0.076 | -0.074 |
| Total Liabilities & Shareholders’ Equity | 129.411 | 165.316 | 128.208 | 148.705 | 139.991 |
| Total Common Shares Outstanding | 34.9533 | 34.739 | 32.4068 | 32.1738 | 32.1738 |
| Other Current Assets, Total | 0 | 0.015 | 0.042 | 0.015 | |
| Total Preferred Shares Outstanding | 0.014 | 0.014 |
- Anual
- Trimestral
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -80.051 | -74.766 | -78.166 | -56.024 | 95.639 |
| Efectivo de actividades de explotación | -55.154 | -69.037 | -48.761 | -48.029 | 104.084 |
| Efectivo de actividades de explotación | 1.479 | 1.605 | 1.664 | 1.247 | 1.008 |
| Partidas no monetarias | 15.585 | 14.849 | 11.693 | 2.778 | 9.91 |
| Cash Taxes Paid | 0 | 0.459 | 0.123 | 1.9 | |
| Intereses pagados en efectivo | 0 | 0.648 | |||
| Cambios en el capital circulante | 7.833 | -10.725 | 16.048 | 3.97 | -2.473 |
| Efectivo de actividades de inversión | 52.458 | 0.344 | 82.583 | 37.903 | -121.307 |
| Gastos de capital | -0.255 | -0.21 | -0.685 | -2.869 | -0.947 |
| Otras partidas de flujo de caja de inversión, total | 52.713 | 0.554 | 83.268 | 40.772 | -120.36 |
| Efectivo procedente de actividades de financiación | 67.13 | 92.852 | 1.451 | -0.169 | 5.49 |
| Elementos de flujo de caja de financiación | 2.575 | 21.955 | |||
| Emisión (retiro) de acciones, neto | 64.555 | 70.897 | 1.451 | -0.169 | 6.576 |
| Emisión (amortización) de deuda, neta | 0 | -1.086 | |||
| Variación neta de la tesorería | 64.434 | 24.159 | 35.273 | -10.295 | -11.733 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -37.728 | -80.051 | -43.922 | -17.244 | -22.669 |
| Cash From Operating Activities | -32.324 | -55.154 | -28.676 | -10.04 | -20.714 |
| Cash From Operating Activities | 0.321 | 1.479 | 1.153 | 0.785 | 0.392 |
| Non-Cash Items | 4.119 | 15.585 | 9.535 | 6.419 | 2.258 |
| Changes in Working Capital | 0.964 | 7.833 | 4.558 | 0 | -0.695 |
| Cash From Investing Activities | -49.949 | 52.458 | 52.474 | 52.573 | 30.62 |
| Capital Expenditures | -0.092 | -0.255 | -0.239 | -0.14 | -0.092 |
| Other Investing Cash Flow Items, Total | -49.857 | 52.713 | 52.713 | 52.713 | 30.712 |
| Cash From Financing Activities | 0 | 67.13 | 2.664 | 2.664 | 2.664 |
| Financing Cash Flow Items | 0 | 2.575 | 0 | 0 | 2.575 |
| Issuance (Retirement) of Stock, Net | 0 | 64.555 | 2.664 | 2.664 | 0.089 |
| Net Change in Cash | -82.273 | 64.434 | 26.462 | 45.197 | 12.57 |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group500K+
Traders
92K+
Clientes activos mensualmente
$53M+
Volumen mensual de inversión
$30M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Concert Pharm Company profile
Sobre Concert Pharmaceuticals Inc
Concert Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase clínica. La empresa se centra en el desarrollo de medicamentos de moléculas pequeñas que se descubren mediante la aplicación de su plataforma de entidades químicas deuteradas, la plataforma DCE. Su plataforma DCE permite a la empresa diseñar fármacos candidatos para crear propiedades diferenciadas y atender las necesidades de los pacientes. El candidato principal de la empresa, el CTP-543, que está evaluando en un programa clínico de fase III para el tratamiento de la alopecia areata, una grave enfermedad dermatológica autoinmune. El CTP-543 es un inhibidor selectivo oral de las quinasas Janus JAK1 y JAK2. El CTP-543 se descubrió aplicando su tecnología de química del deuterio para modificar el ruxolitinib, un inhibidor de la Janus quinasa, o JAK, que se comercializa con el nombre de Jakafi en Estados Unidos para el tratamiento de ciertos trastornos sanguíneos y de la enfermedad de injerto contra huésped. La empresa también está evaluando una serie de candidatos en fase de desarrollo.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 3000N
65 Hayden Avenue
LEXINGTON
MASSACHUSETTS 02421
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 500.000 traders de todo el mundo que eligen operar con Capital.com